Some recent studies demonstrated increased pathological complete response (pCR) rates when adding bevacizumab to the NT in patients with Her-2 negative expression, especially in triple-negative breast cancer (TNBC) type. Here, ERBB2 is linked to triple-negative breast carcinoma.